- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Vor Biopharma: Vor Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update | 604 | GlobeNewswire (Europe) | Enrollment on track for Phase 3 UPSTREAM MG trial of telitacicept in generalized myasthenia gravis patients with topline results anticipated in 1H27 Enrollment ongoing for Phase 3 UPSTREAM SjD of... ► Artikel lesen | |
| Mi | Vor Biopharma reports Q1 results | 3 | Seeking Alpha | ||
| VOR BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| Mi | Vor Biopharma Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 07.05. | Wall Street Analysts Believe Vor Biopharma (VOR) Could Rally 124.59%: Here's is How to Trade | 5 | Zacks | ||
| 04.05. | Vor Biopharma: Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 15.04. | H.C. Wainwright senkt Kursziel für Vor Biopharma auf 31 US-Dollar | 1 | Investing.com Deutsch | ||
| 15.04. | H.C. Wainwright lowers Vor Biopharma price target to $31 | 1 | Investing.com | ||
| 08.04. | Stifel reiterates Vor Biopharma stock rating on drug potential | 1 | Investing.com | ||
| 08.04. | Stifel bekräftigt Kaufempfehlung für Vor Biopharma wegen Medikamentenpotenzial | 1 | Investing.com Deutsch | ||
| 01.04. | Vor Biopharma: Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) | ||
| 30.03. | Stifel cuts Vor Biopharma stock price target on financing assumptions | 2 | Investing.com | ||
| 30.03. | Stifel senkt Kursziel für Vor Biopharma aufgrund neuer Finanzierungsannahmen | 2 | Investing.com Deutsch | ||
| 30.03. | Vor Biopharma reports Q4 results | 2 | Seeking Alpha | ||
| 30.03. | Vor Bio doses first patient in phase 3 Sjögren's disease trial | 1 | Investing.com | ||
| 30.03. | Vor Biopharma: Vor Bio Doses First Patient in Global Phase 3 UPSTREAM SjD Registrational Trial of Telitacicept in Primary Sjögren's Disease | 279 | GlobeNewswire (Europe) | BOSTON, March 30, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the dosing of the first... ► Artikel lesen | |
| 30.03. | Vor Biopharma: Vor Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update | 287 | GlobeNewswire (Europe) | First patient dosed in UPSTREAM SjD, a global Phase 3 clinical trial assessing telitacicept in primary Sjögren's disease $75 million private placement strengthens balance sheet and supports telitacicept... ► Artikel lesen | |
| 30.03. | Vor Biopharma Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 30.03. | Vor Biopharma Inc. - 10-K, Annual Report | - | SEC Filings | ||
| 29.03. | Jefferies startet Vor Biopharma mit Kaufempfehlung nach strategischer Neuausrichtung | 6 | Investing.com Deutsch | ||
| 29.03. | Jefferies initiates Vor Biopharma stock with buy rating on autoimmune pivot | 1 | Investing.com |
1 2 3 Weiter >>
53 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CRISPR THERAPEUTICS | 42,070 | -3,22 % | 1 Top Wall Street Analyst Thinks CRISPR Therapeutics Could More Than Double. Should You Buy the Stock Hand Over Fist? | ||
| EDITAS MEDICINE | 2,320 | -5,69 % | Editas Medicine, Inc.: Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting | CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, shared new preclinical... ► Artikel lesen | |
| GERON | 1,155 | -3,99 % | Geron Corporation: First Real-World Evidence Study of RYTELO (imetelstat) in Lower-risk Myelodysplastic Syndromes (LR-MDS) to be Presented at EHA 2026 | ||
| SOL GLOBAL INVESTMENTS | 0,026 | -100,00 % | CSE Bulletin: Suspension - SOL Global Investments Corp. (SOL) | Le 7 avril/April 2026
Effective immediately, SOL Global Investments Corp. is suspended pursuant to CSE Policy 3. The suspension is considered a Regulatory Halt as defined in National Instrument 23-101... ► Artikel lesen | |
| FATE THERAPEUTICS | 1,580 | -7,06 % | Fate Therapeutics, Inc.: Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates | RECLAIM - LN, a Phase 2 potentially registrational clinical trial of FT819 in patients with refractory moderate-to-severe systemic lupus erythematosus (SLE) with lupus nephritis, on schedule to initiate... ► Artikel lesen | |
| TRINITY BIOTECH | 0,584 | +0,09 % | Trinity Biotech plc: Trinity Biotech Appoints Jerry Lydon to Lead North America Commercial Operations | - Appointment supports revenue quality and profitability momentum as the Company activates its transformed operating base - Company announces further operational progress in its Comprehensive Transformation... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 7,430 | -5,11 % | Arcturus outlines 12-week ARCT-032 Phase II enrollment and extends cash runway beyond Q2 2028 | ||
| OVID THERAPEUTICS | 2,360 | 0,00 % | B.Riley reiterates Buy on Ovid Therapeutics stock, $5 target | ||
| CERVOMED | 3,140 | -2,48 % | CervoMed Inc. - 10-Q, Quarterly Report | ||
| EQUILLIUM | 2,100 | +1,94 % | Equillium, Inc.: Equillium Reports First Quarter 2026 Financial Results and Corporate Highlights | Phase 1 proof-of-mechanism study of EQ504 on track to initiate in mid-2026, with data expected approximately six months thereafter Equillium appoints Snehal Naik, Ph.D., as Chief Development Officer... ► Artikel lesen | |
| CABALETTA BIO | 3,380 | -6,37 % | Cabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update | Preconditioning-free (PC-free) 6-to-9-month clinical data with a single infusion of the lowest dose of rese-cel in the RESET-PV- study presented today at ASGCT 2026 Annual Meeting along with initial... ► Artikel lesen | |
| 4D MOLECULAR THERAPEUTICS | 9,300 | -5,20 % | 4D Molecular Therapeutics, Inc.: 4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones | Completed enrollment in 4D-150 4FRONT-1 wet AMD Phase 3 trial within approximately 11 months, ahead of initial projections and reflecting strong interest from investigators and patients; topline data... ► Artikel lesen | |
| REGENCELL BIOSCIENCE | 29,110 | +8,18 % | Regencell Bioscience Holdings Ltd - 6-K, Report of foreign issuer | ||
| THX PHARMA | 3,440 | +2,08 % | THERANEXUS: THX Pharma Publishes Its 2025 Annual Results, Cash Position as of March 31, 2026, and Provides a Business Update | Lyon, France - April 28, 2026 - 7:00 p.m. CEST - THX Pharma (Theranexus), an innovative biopharmaceutical company specializing in the treatment of rare neurological diseases, today announces its... ► Artikel lesen | |
| LONGEVERON | 0,653 | -7,06 % | Longeveron Announces Constructive Type C Meeting with U.S. FDA Ahead of Data Readout for ELPIS II Phase 2b Clinical Trial Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS) | MIAMI, May 08, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic... ► Artikel lesen |
Das Unternehmen VOR BIOPHARMA INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -1,79 % bei einem Aktienkurs von 14,800 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VOR BIOPHARMA INC finden Sie auf Wallstreet Online.